Advanced

Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study

Altman, Daniel; Granath, Fredrik; Mattiasson, Anders LU and Falconer, Christian (2009) In International Urogynecology Journal 20(11). p.1285-1291
Abstract
Nationwide use and costs of anticholinergic drug for overactive bladder are unknown. We performed a nationwide study based on the Swedish Register on Prescribed Pharmaceuticals. From 2000 to 2007, there was a 68.8% increase in dispensed anticholinergic drugs in a population of 9 million. More than 93 million DDDs (calculated average maintenance dose per day) of anticholinergic drugs were dispensed corresponding to an overall DDD/TID (DDD per 1,000 inhabitants per day) of 3.5 per 1,000 persons per year. Approximately two thirds of anticholinergic drugs were prescribed to women, regardless of drug type. In 2007, the cost for anticholinergic drugs was 22 million a,not sign of which tolterodine comprised 70.8%. Solifenacin and darifenacin... (More)
Nationwide use and costs of anticholinergic drug for overactive bladder are unknown. We performed a nationwide study based on the Swedish Register on Prescribed Pharmaceuticals. From 2000 to 2007, there was a 68.8% increase in dispensed anticholinergic drugs in a population of 9 million. More than 93 million DDDs (calculated average maintenance dose per day) of anticholinergic drugs were dispensed corresponding to an overall DDD/TID (DDD per 1,000 inhabitants per day) of 3.5 per 1,000 persons per year. Approximately two thirds of anticholinergic drugs were prescribed to women, regardless of drug type. In 2007, the cost for anticholinergic drugs was 22 million a,not sign of which tolterodine comprised 70.8%. Solifenacin and darifenacin steadily increased their DDD/TIDs after market introduction. In this nationwide study, there was a 70% increased rate of expedited prescriptions of anticholinergic drugs for the treatment of overactive bladder in a relatively stable population. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Drug, Anticholinergic, Cost, Overactive bladder
in
International Urogynecology Journal
volume
20
issue
11
pages
1285 - 1291
publisher
Springer
external identifiers
  • wos:000270871500002
  • scopus:75549091224
ISSN
1433-3023
DOI
10.1007/s00192-009-0957-z
language
English
LU publication?
yes
id
bd2de0de-3441-44a2-bf29-e4479ce03c02 (old id 1506333)
date added to LUP
2009-11-23 14:04:49
date last changed
2017-02-22 11:44:09
@article{bd2de0de-3441-44a2-bf29-e4479ce03c02,
  abstract     = {Nationwide use and costs of anticholinergic drug for overactive bladder are unknown. We performed a nationwide study based on the Swedish Register on Prescribed Pharmaceuticals. From 2000 to 2007, there was a 68.8% increase in dispensed anticholinergic drugs in a population of 9 million. More than 93 million DDDs (calculated average maintenance dose per day) of anticholinergic drugs were dispensed corresponding to an overall DDD/TID (DDD per 1,000 inhabitants per day) of 3.5 per 1,000 persons per year. Approximately two thirds of anticholinergic drugs were prescribed to women, regardless of drug type. In 2007, the cost for anticholinergic drugs was 22 million a,not sign of which tolterodine comprised 70.8%. Solifenacin and darifenacin steadily increased their DDD/TIDs after market introduction. In this nationwide study, there was a 70% increased rate of expedited prescriptions of anticholinergic drugs for the treatment of overactive bladder in a relatively stable population.},
  author       = {Altman, Daniel and Granath, Fredrik and Mattiasson, Anders and Falconer, Christian},
  issn         = {1433-3023},
  keyword      = {Drug,Anticholinergic,Cost,Overactive bladder},
  language     = {eng},
  number       = {11},
  pages        = {1285--1291},
  publisher    = {Springer},
  series       = {International Urogynecology Journal},
  title        = {Anticholinergic drug use for overactive bladder in Sweden: a nationwide pharmacoepidemiological study},
  url          = {http://dx.doi.org/10.1007/s00192-009-0957-z},
  volume       = {20},
  year         = {2009},
}